Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.
Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.
Lupoli
G
G
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Facoltà di Medicina e Chirurgia, Università Federico II, Napoli, Italy.
Di Carlo
C
C
Nuzzo
V
V
Vitale
G
G
Russo
D
D
Palomba
S
S
Nappi
C
C
D000152:Acne Vulgaris / Q000188:drug therapy / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists* / Q000627:therapeutic use*; D006628:Hirsutism / Q000188:drug therapy / Q000209:etiology; D006728:Hormones / Q000097:blood; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D011498:Protein Precursors / Q000009:adverse effects / Q000627:therapeutic use*
D006728:Hormones; D011498:Protein Precursors; C050502:gonadotropin releasing hormone associated peptide; D007987:Gonadotropin-Releasing Hormone